Hall John E, do Carmo Jussara M, da Silva Alexandre A, Wang Zhen, Hall Michael E
From the Departments of Physiology and Biophysics (J.E.H., J.M.d.C., A.A.d.S., Z.W., M.E.H.), Medicine (M.E.H.), Mississippi Center for Obesity Research (J.E.H., J.M.d.C., A.A.d.S., Z.W., M.E.H.), and Cardiovascular-Renal Research Center (J.E.H., J.M.d.C., A.A.d.S., Z.W., M.E.H.), University of Mississippi Medical Center, Jackson.
Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.
Excess weight gain, especially when associated with increased visceral adiposity, is a major cause of hypertension, accounting for 65% to 75% of the risk for human primary (essential) hypertension. Increased renal tubular sodium reabsorption impairs pressure natriuresis and plays an important role in initiating obesity hypertension. The mediators of abnormal kidney function and increased blood pressure during development of obesity hypertension include (1) physical compression of the kidneys by fat in and around the kidneys, (2) activation of the renin-angiotensin-aldosterone system, and (3) increased sympathetic nervous system activity. Activation of the renin-angiotensin-aldosterone system is likely due, in part, to renal compression, as well as sympathetic nervous system activation. However, obesity also causes mineralocorticoid receptor activation independent of aldosterone or angiotensin II. The mechanisms for sympathetic nervous system activation in obesity have not been fully elucidated but may require leptin and activation of the brain melanocortin system. With prolonged obesity and development of target organ injury, especially renal injury, obesity-associated hypertension becomes more difficult to control, often requiring multiple antihypertensive drugs and treatment of other risk factors, including dyslipidemia, insulin resistance and diabetes mellitus, and inflammation. Unless effective antiobesity drugs are developed, the effect of obesity on hypertension and related cardiovascular, renal and metabolic disorders is likely to become even more important in the future as the prevalence of obesity continues to increase.
体重过度增加,尤其是与内脏脂肪增多相关时,是高血压的主要原因,占人类原发性(特发性)高血压风险的65%至75%。肾小管钠重吸收增加会损害压力性利钠作用,并在肥胖相关性高血压的发病中起重要作用。肥胖相关性高血压发展过程中,肾功能异常和血压升高的介导因素包括:(1)肾脏内及周围脂肪对肾脏的物理压迫;(2)肾素-血管紧张素-醛固酮系统激活;(3)交感神经系统活动增强。肾素-血管紧张素-醛固酮系统的激活可能部分归因于肾脏受压以及交感神经系统激活。然而,肥胖还会导致盐皮质激素受体激活,且不依赖于醛固酮或血管紧张素II。肥胖时交感神经系统激活的机制尚未完全阐明,但可能需要瘦素和脑黑皮质素系统的激活。随着肥胖时间延长和靶器官损伤的发展,尤其是肾脏损伤,肥胖相关性高血压变得更难控制,常常需要多种降压药物以及对其他危险因素进行治疗,包括血脂异常、胰岛素抵抗、糖尿病和炎症。除非研发出有效的抗肥胖药物,否则随着肥胖患病率持续上升,肥胖对高血压及相关心血管、肾脏和代谢紊乱的影响在未来可能会变得更加重要。